From a pharmaceutical point of view, it is to date entirely unclear whether or not neurological disorders caused by mutations in the TAF2 gene develop due to altered regulation of transcriptional activity or due to other currently unknown mechanisms. This evidence concerns the gene TAF2 and nervous system disorder.